Tag Archives: 73rd Scientific Sessions®

Boehringer Ingelheim, Lilly released results of new meta-analysis regarding CV events in linagliptin Phase 3 trials presented at the American Diabetes Association

Ingelheim, Germany and Indianapolis, US, 1-7-2013 — /europawire.eu/ — Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with … Read the full press release